Novartis Lifts Forecasts After Profit Beat
Wall Street Journal
Novartis posted slightly higher earnings and sales for the first quarter, beating analysts’ expectations, said the planned spinoff of Sandoz remained on track for the second half of 2023, and raised its fiscal guidance.